Those 2 penny stocks could rally as much as $ 11, analysts say
At its January FOMC meeting, the Federal Reserve held rates steady – they are currently near their lows, and unsurprisingly, the Fed is holding them there. Fed chairman Jerome Powell may have fed some market pessimism when speaking after the meeting, pointing out that unemployment has risen in recent months. For market watchers seeking support, there is consolation in the Fed’s monetary policy. The central bank has pledged to buy $ 80 billion worth of Treasury bills every month, and is expected to put a rate hike on hold until 2023. At least one top strategist sees the current market environment in terms of opportunities. JPMorgan strategist Marko Kolanovic takes an optimistic stance and writes: “We assume that the global COVID pandemic will decrease rapidly in the coming weeks. In fact, the pace of decline in new cases in the past two weeks is the fastest ever in the US and worldwide. Central banks should remain accommodative amid rising unemployment and over a decade of low inflation that is below their targets – term turmoil like this week provides an opportunity to switch from bonds to stocks. “With that outlook in mind, we set out to find exciting opportunities that won’t break the bank, namely penny stocks. Priced at $ 5 or less, these stocks offer investors the highest growth potential available in the market. Again, there is a risk as the “pennies” are often cheap for a reason. Careful examination is therefore essential. Using TipRanks’ database, we identified two penny stocks that received a consensus rating of “Strong Buy” from the analyst community. Quite z u don’t mention that every company has huge upside potential as some analysts see it spike to $ 11. BioLineRx, Ltd. (BLRX) We’re starting BioLineRx, a clinical-stage biopharmaceutical company focused on developing new cancer treatments. Oncology is an important area for state-of-the-art biopharmaceuticals. Cancer is often fatal and often resisable, consistent with current treatments – and these treatments themselves often cause severe side effects in patients. BioLineRx has an active pipeline of drug candidates. The most advanced, however, is motixafortid, a synthetic peptide that has completed patient enrollment in a phase 3 study to mobilize stem cells for autologous bone marrow transplantation. The drug is being studied for effectiveness in promoting bone marrow harvesting prior to cancer treatment. The results of a pre-planned interim analysis showed « statistically significant evidence for motixafortid treatment at the primary endpoint » so significant that enrollment was completed early with 122 patients instead of 177. Mobilizing stem cells using Motixafortid is believed to be the company’s most efficient route to registering the new drug for regulatory approval. Given the potential of Motixafortide and its share price of $ 2.40, some analysts believe now is the time to pull the trigger. Mark Breidenbach, 5-star analyst at BLRX for Oppenheimer, commented, “Our thesis continues to focus on motixafortid in stem cell mobilization, and we see a disconnect between the company’s market cap and Motixafortid’s market opportunity as a stem cell mobilizer. The main GENESIS secondary endpoints are expected by mid-2021, and we see little risk to this data… ”The analyst added,“ We believe the results of the Phase 3 GENESIS trial could lead the majority of transplant doctors to choose BL-8040 instead of Mozobil with G – Combine CSF if the drug is approved. In addition to our work, BL-8040 contains for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company has a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck and Genentech. “With all of this in mind, Breidenbach rates BLRX as a buy, and its target price of USD 11 points to an uptrend of a whopping 358% for the coming year. (To see Breidenbach’s track record, click here) The rest of the street appears to reflect Breidenbach’s bullish sentiment. With 3 buys and no holds or sells, the consensus is unanimous: BLRX is a strong buy. On top of the good news, the upside is ~ 428% based on the average price target of $ 12.67. (See BLRX stock analysis on TipRanks) Kindred Biosciences (KIN) While most biotech companies focus on human drugs, we’re not the only market. Kindred Biosciences is a biopharmaceutical company in the veterinary market that develops biological medicines to improve the lives of our pets and work animals. The company describes its mission as « bringing to pets the same types of safe and effective medicines that human family members enjoy ». Parvovirus (CPV) is a highly infectious and deadly viral disease that affects dogs. While vaccines are available, untreated cases can have a mortality rate of over 91%. KIND-030, Kindred’s main pipeline drug, is currently being used to treat these r disease developed. The drug candidate is currently pursuing two paths in the development process – one for the treatment of established infections and one for the prophylactic preventive treatment of CPV. The prophylactic study showed positive results, with all dogs treated avoiding infection while all dogs in the placebo group developed parvovirus disease. KIND-030 also showed a mortality benefit when given to treat infections. The drug candidate is in the crucial study phase of development, the last before possible approval. Last month, Kindred announced that it had entered into an agreement with Elanco Animal Health – a major manufacturer of veterinary drugs – to manufacture KIND-030. Cantor analyst Brandon Folkes sees a lot of potential in Kindred, especially in the company’s agreement with Elanco. “A partnership with a leading animal health company, in this case Elanco, is exactly what the company needed from our point of view. From our point of view, this confirms KINs n A new strategic approach as a drug developer in the search for larger trading partners. We believe today’s deal should show investors that Kindred’s pipeline continues to have significant value that could be realized in the next 12 to 18 months, ”said Folkes. Kindred is also conducting studies with tirnovetmab or KIND-016, an antibody directed against IL31, for the treatment of atopic dermatitis in dogs. The pivotal efficacy study of this drug began in the final quarter of 2020. There is a potentially huge market for successful dermatitis treatment in dogs. Over the past six years, there has been a 47% increase in veterinary visits for dogs with severely itchy skin and the market is valued at $ 900 million or more. « W While 2020 was a tough year for KIN stock, the company continued to take multiple shots on goal from its diversified pipeline that could reward investors at the current level. With multiple readings in 2021 and once again focusing solely on developing its pipeline, we anticipate that 2021 could be a banner year for KIN should it be able to deliver on the promise of its pipeline and, in particular, its atopic dermatitis portfolio, » so the analyst summarized. To that end, Folkes gives KIN a target price of $ 11, which means an upside potential of 139% for 2021 and an overweight (i.e. buy). (To see Folkes’ success story, click here.) Kindred is another company with a unanimous consensus from Strong Buy analysts based on 5 recent Buy ratings. The stock has an average price target of $ 10.25, indicating ~ 124% growth from the current trading price of $ 4.59. (See KIN Stock Analysis on TipRanks.) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is important that you do your own research before making any investment.
Is Investing Com a Reliable Source?
Yes, http://Investing.com seems reliable and real-time.
What’s the best app to invest in?
The 8 Best Investing App Alternatives To Robinhood
- TD Ameritrade.
- E * TRADE.
- Ally Invest.
- Cash app.
How can I become a millionaire?
8 tips to become a millionaire
- Avoid Debt.
- Invest early.
- Get serious about your savings.
- Increase your income to reach your goal faster.
- Reduce unnecessary expenses.
- Keep your millionaire goal in the foreground and center.
- Work with an investing professional.
- Put your plan on repetition.
How accurate is the technical bearing analysis?
Technical analysis can provide very accurate price predictions. Many beginners expect recommendations from technical analysts or software samples to be 100 percent correct. … Technical analysis is also about probabilities and probabilities, not guarantees.
Are technical indicators useless?
You can discount any indicators that are designed to predict market movement. Taken alone, they are not a predictive trading system. Technical indicators are only useful as part of a full reactive trading system. … In addition, a technical indicator is meaningless in itself.
What is the best stock chart software?
Here are some of the best free real-time stock chart platforms to check out.
- TradingView. TradingView provides real-time stock charts that are visually appealing and can be customized with hundreds of technical indicators. …
- StockCharts. …
- Google Finance.
Does Warren Buffett use technical analysis?
Academics largely view technical analysis as pseudoscientific nonsense. … Buffett said he « discovered that technical analysis was not working when I turned the chart upside down and got no other answer ». For Lynch, charts are “great for predicting the past”.
Is investing com free?
Our basic services are free, but we may offer you paid upgrades for more advanced features such as the ad-free version of the services (Ad-free Services).
Can You Get Rich In Stocks?
You can get rich in stocks, you just have to take the risk. You can create wealth by putting your money on the stock market over a long period of time. … The key to success is that you can’t get rich with stocks without taking some risk. Personally, I think it’s worth the risk.
What are the 4 types of investments?
There are four main investment types or asset classes to choose from, each with different characteristics, risks and benefits.
- Growth investments. …
- Shares. …
- Property. …
- Defensive investments. …
- Cashbox. …
- Fixed interest.
Which stocks should I buy today?
|Company name||CREATE DATE / TIME||TARGET PRICE|
|UPL||January 16, 2020 12:47 p.m.||Goal 596-600|
|Sun Pharma.Inds.||January 16, 2020 12:47 p.m.||Goal 460-462|
|Kotak Mah. Bank||January 16, 2020 12:47 p.m.||Goal 1706-1710|
Why doesn’t investing COM work?
Make sure that anti-virus programs (McAfee, Kaspersky Antivirus or an analogue) or a firewall installed on your computer are not blocking access to INVESTING.COM. DNS cache. VPN and alternative DNS services. Browser plugins.
How do I invest in com?
How to Invest: Basic Investment Strategies
- Stay varied. When deciding to invest, keep age in mind: never put all your eggs in one basket. …
- Spread the risk. Large-cap mutual funds that invest in domestic stocks are a good growth strategy. …
- Averaging the rupee costs. …
- Asset allocation. …
- Do your homework.
How do I invest money?
Learn how to invest in the stock market.
- Decide how much help you want to invest. …
- Give your money a goal and set a deadline. …
- Choose an investment account. …
- Open your account. …
- Choose investments that suit your risk tolerance.
Where should I put my money now?
Here is a look at the top 10 investment opportunities Indians are looking at while saving for their financial goals.
- Direct equity. …
- Equity funds. …
- Debt funds. …
- National Pension System (NPS) …
- Public Provident Fund (PPF) …
- Bank time deposit (FD) …
- Savings program for seniors (SCSS) …
- Real estate.